AB Science SA (AB) AI Stock Analysis

• Market Cap: $89.83M
• Dividend Yield: N/A
• Average Volume (3M): 227.66K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.74
• Revenue Growth: 10.52%
• EPS Growth: 30.56%
• Country: FR
• Employees: 40
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.09
• Shares Outstanding: 63,706,917
• 10 Day Avg. Volume: 279,892
• 30 Day Avg. Volume: 227,663
• PEG Ratio: 0.23
• Price to Book (P/B): -1.98
• Price to Sales (P/S): 43.83
• P/FCF Ratio: 127.00
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 44.33
• Enterprise Value/Gross Profit: 38.08
• Enterprise Value/Ebitda: -7.22
• 1Y Price Target: $3.02
• Price Target Upside: 120.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 45 Neutral
• Price Target: €1.00 ▼(-27.01% Downside)

AB Science SA's overall stock score is primarily impacted by its poor financial performance, with significant operational and financial risks. Technical analysis provides mixed signals, and the negative P/E ratio further highlights valuation concerns. The absence of earnings call data and corporate events does not alter the risk profile.

AB Science SA Business Overview & Revenue Model

Company Description

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

How the Company Makes Money

AB Science primarily makes money through the development and commercialization of its therapeutic products. The company's revenue model is largely based on the successful progression of its drug candidates through clinical trials, leading to potential market approval and subsequent sales. Key revenue streams include milestone payments from partnerships with larger pharmaceutical companies, royalties from product sales, and potential licensing agreements. The company may also benefit from grants and funding for research initiatives, as well as collaborations with academic institutions and other biotech firms, which can enhance its research capabilities and market reach.

AB Science SA Financial Statement Overview

Summary

AB Science SA faces significant financial challenges, with negative EBIT and net income, negative equity, and reliance on financing activities. Despite slight improvements in cash flow and revenue growth, the company remains unprofitable and financially unstable.

Income Statement

The income statement shows a challenging financial position for AB Science SA. Despite a slight increase in revenue in 2024, the company has consistently reported negative EBIT and net income, indicating ongoing operational challenges. The gross profit margin has improved, but net profit margins are significantly negative due to high operating losses. Revenue growth is positive but modest, and the company remains unprofitable, reflecting instability in its revenue generation and cost management.

Balance Sheet

AB Science SA's balance sheet reveals significant financial risk with negative stockholders' equity, indicating more liabilities than assets. The debt-to-equity ratio cannot be calculated due to negative equity, highlighting potential solvency concerns. While the cash balance is relatively stable, total liabilities consistently exceed total assets, reflecting a leveraged position and financial instability.

Cash Flow

The cash flow statement indicates some improvement in cash flow management in 2024, with positive operating cash flow and free cash flow. However, historical data shows persistent negative free cash flow, indicating challenges in generating sufficient cash from operations. The free cash flow to net income ratio is not meaningful due to negative net income. The company's reliance on financing activities to support cash flow is evident, suggesting potential liquidity risks.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.07M	970.00K	958.00K	1.61M	1.58M
Gross Profit	1.25M	587.00K	927.00K	1.50M	1.51M
EBITDA	-4.92M	-12.80M	-13.41M	-17.36M	-17.10M
Net Income	-7.83M	-10.05M	-13.62M	-14.46M	-15.04M
Balance Sheet
Total Assets	23.18M	25.50M	23.84M	21.27M	29.69M
Cash, Cash Equivalents and Short-Term Investments	7.99M	6.07M	7.27M	8.72M	20.66M
Total Debt	18.47M	19.10M	23.96M	8.35M	7.06M
Total Liabilities	46.93M	46.51M	59.51M	44.47M	49.24M
Stockholders Equity	-23.75M	-21.01M	-35.67M	-23.20M	-19.55M
Cash Flow
Free Cash Flow	370.00K	-17.22M	-18.11M	-17.74M	-13.88M
Operating Cash Flow	525.00K	-16.87M	-17.47M	-17.18M	-13.51M
Investing Cash Flow	-136.00K	-614.00K	-360.00K	-590.00K	-277.00K
Financing Cash Flow	1.53M	16.27M	16.39M	5.84M	28.73M

AB Science SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AB, the sentiment is Positive. The current price of 1.37 is above the 20-day moving average (MA) of 1.29, above the 50-day MA of 1.28, and below the 200-day MA of 1.37, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 61.58 is Neutral, neither overbought nor oversold. The STOCH value of 68.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:AB.

AB Science SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OSE	70 Outperform	€157.13M	3.80	86.78%	―	3037.72%	―
TNG	55 Neutral	€165.50M	―	-220.48%	―	111.76%	-22.45%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALSEN	49 Neutral	€109.72M	―	-40.00%	―	―	10.87%
AB	45 Neutral	$89.83M	―	―	―	10.52%	30.56%
IPH	40 Neutral	$164.05M	―	-271.32%	―	-75.86%	-30.54%